Cureality Proficiency Certifications and Awards X
Inner Circle Forums

Portions of the Undoctored Inner Circle Member Forum and its vast wealth of knowledge, are available only to our Members.
Becoming an Inner Circle Member will allow you to post topics, ask Dr. Davis questions, and view all replies.

GlycA test. Anyone had one or heard of it?

Member Forum >> Coronary Disease & Cholesterol Protocol >> GlycA test. Anyone had one or heard of it?


No Avatar

Join Date: 5/18/2019
Posts Contributed: 269
Total Likes: 36
Recommends Recd: 0
Ignores Issued: 0
Certs & Awards: 0   view

Likes Recd: 0
Posted: 9/21/2020 12:03:20 AM
Edited: 9/21/2020 12:12:52 AM (1)

Offered here for $28

About all I can say is that it is general test of antibody presence from cytokines and looks like it might be as useful as the more specific antibody tests that the data is coalesced from.

I’ll be ordering it with my next trip to the lab in early October.

Here is an abstract of it’s why and wherefore:


The GlycA test is a recently developed proton nuclear magnetic resonance (1H-NMR) spectroscopy-based assay that has been gaining increased interest as a serum biomarker for systemic inflammation, and consequently, as a potential biomarker for cardiovascular disease (CVD) risk assessment.

The test has undergone investigation in several large cohort studies, since its development, to assess its predictive value for incident CVD events, CVD-associated mortality, and all-cause mortality. Despite variation in the generated estimates by these studies, they have all consistently demonstrated moderate-strength positive correlations between baseline GlycA levels, and incident CVD event rates and associated mortality. These correlations withheld testing even after adjusting for several other established CVD risk factors, including notable inflammatory biomarkers such as high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6). Compared with hsCRP, which is a well-known inflammatory biomarker for CVD risk assessment, GlycA has a comparable predictive value for future CVD-related events. However, the indications to pursue GlycA testing, and its clinical utility in patient care management, are yet to be determined.

In this review, we define the GlycA test and what it “measures”, and provide a brief summary of the findings of studies showing its association with incident CVD rates, and CVD-related mortality, as well as its correlation with other inflammatory biomarkers, namely hsCRP. Finally, we highlight the analytical advantages of the GlycA test, compared with “traditional” inflammatory biomarkers, while also mentioning its current limitations.